Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines
Conditions
Interventions
LOU064 25 mg (b.i.d)
Placebo
+1 more
Locations
112
United States
Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
North Little Rock, Arkansas, United States
Novartis Investigative Site
Bakersfield, California, United States
Novartis Investigative Site
Lancaster, California, United States
Novartis Investigative Site
Los Angeles, California, United States
Novartis Investigative Site
Redwood City, California, United States
Start Date
November 30, 2021
Primary Completion Date
December 27, 2023
Completion Date
January 19, 2024
Last Updated
April 8, 2025
NCT07358364
NCT06931405
NCT06873516
NCT07230418
NCT07219615
NCT07021495
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions